Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer... Show more
Industry Biotechnology
The Moving Average Convergence Divergence (MACD) for GNMSF turned positive on May 13, 2026. Looking at past instances where GNMSF's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GNMSF advanced for three days, in of 217 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on May 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GNMSF as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Aroon Indicator for GNMSF entered a downward trend on May 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.